The seasonal window for respiratory syncytial virus protection opens next month, which turns an abstract choice into a scheduling decision for any household expecting a baby this fall.
There are two routes to protection, and for most infants, only one is needed. A pregnant patient can receive the maternal RSV vaccine, Pfizer's Abrysvo, between 32 and 36 weeks of gestation. Or the baby can receive a long-acting monoclonal antibody after birth. Either path is intended to cover the same stretch of life, the first months, when an infant's airways are smallest, and the hospitalization risk is highest.
